- Home
- LCTX vs COLA Comparison
LCTX vs COLA Comparison
Compare LCTX & COLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- COLA
- Stock Information
- Founded
- LCTX 1990
- COLA 2024
- Country
- LCTX United States
- COLA Singapore
- Employees
- LCTX N/A
- COLA N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- COLA
- Sector
- LCTX Health Care
- COLA
- Exchange
- LCTX Nasdaq
- COLA NYSE
- Market Cap
- LCTX 95.2M
- COLA 79.8M
- IPO Year
- LCTX N/A
- COLA 2025
- Fundamental
- Price
- LCTX $0.49
- COLA $10.09
- Analyst Decision
- LCTX Strong Buy
- COLA
- Analyst Count
- LCTX 5
- COLA 0
- Target Price
- LCTX $4.20
- COLA N/A
- AVG Volume (30 Days)
- LCTX 860.2K
- COLA 55.0K
- Earning Date
- LCTX 05-13-2025
- COLA 01-01-0001
- Dividend Yield
- LCTX N/A
- COLA N/A
- EPS Growth
- LCTX N/A
- COLA N/A
- EPS
- LCTX N/A
- COLA N/A
- Revenue
- LCTX $9,557,000.00
- COLA N/A
- Revenue This Year
- LCTX N/A
- COLA N/A
- Revenue Next Year
- LCTX $232.66
- COLA N/A
- P/E Ratio
- LCTX N/A
- COLA N/A
- Revenue Growth
- LCTX 19.42
- COLA N/A
- 52 Week Low
- LCTX $0.37
- COLA $9.95
- 52 Week High
- LCTX $1.40
- COLA $10.10
- Technical
- Relative Strength Index (RSI)
- LCTX 54.19
- COLA N/A
- Support Level
- LCTX $0.45
- COLA N/A
- Resistance Level
- LCTX $0.49
- COLA N/A
- Average True Range (ATR)
- LCTX 0.03
- COLA 0.00
- MACD
- LCTX 0.00
- COLA 0.00
- Stochastic Oscillator
- LCTX 72.25
- COLA 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About COLA COLUMBUS ACQUISITION CORP
Columbus Acquisition Corp is a blank check company.